{"entity":{"id":"nct07827261","kind":"trial","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of izalontamab brengitecan and glecirasib in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07827261 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 36 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1; Glecirasib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: \"Patients with locally advanced or metastatic non-small cell lung cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07827261","url":"https://clinicaltrials.gov/study/NCT07827261"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["kras-g12c-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["izalontamab-brengitecan","glecirasib"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07827261","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07827261/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}